Publications by authors named "Illia Gumenchuk"
Article Synopsis
- There is a pressing need for new treatments for serious infections caused by Gram-negative bacteria, which the REVISIT study examined by evaluating aztreonam-avibactam against standard treatments in complicated infections.
- The study involved a multinational, open-label design with adults who had complicated intra-abdominal infections or hospital-acquired pneumonia, comparing aztreonam-avibactam with meropenem or colistin over 5-14 days.
- Results showed that out of 422 enrolled patients, 64% had identified Gram-negative pathogens, and the study aimed to determine clinical cure rates and safety without formal hypothesis testing.
Background: The development of novel broad-spectrum antibiotics, with efficacy against both gram-positive and gram-negative bacteria, has the potential to enhance treatment options for acute bacterial skin and skin structure infections (ABSSSIs). Ceftobiprole is an advanced-generation intravenous cephalosporin with broad in vitro activity against gram-positive (including methicillin-resistant Staphylococcus aureus) and gram-negative pathogens.
Methods: TARGET was a randomized, double-blind, active-controlled, parallel-group, multicenter, phase 3 noninferiority study that compared ceftobiprole with vancomycin plus aztreonam.